Monthly Archives: December 2019

Eri Anton, a Latina Social Media Fitness Star and Entrepreneur, Reaches the 1 Million Followers Milestone on Instagram

Anton Encourages Women of All Shapes and Sizes to Be Proud of their Bodies

LOS ANGELES, CA / ACCESSWIRE / December 17, 2019 / Eri Anton, a Latina social media fitness star and successful entrepreneur, is pleased to announce that she has achieved a very significant milestone: 1 million followers on Instagram.

To learn more about Anton, please check out her Instagram page at www.instagram.com/erianton_.

As a spokesperson for Anton noted, she is creating a lot of buzz in the world of social media. The intelligent Latina is not only beautiful, but also an entrepreneur and aspiring businesswoman.

This year, Anton also launched her website EriAnton.com, which, like her Instagram page, has experienced lots of traffic. She has also begun writing blogs and posting on her site content related to health/fitness as well as other areas of life she feels will benefit others.

"Eri has a section on her site related to the ‘Fit Life' and she wants to encourage and motivate women of all shapes and sizes to be proud of their bodies and work hard to be the best they can be," the spokesperson noted, adding that Anton truly has a heart for women and the pressures society places on them and their looks and wants to help redefine what beauty really is.

"The most beautiful women glow on the outside from a beautiful inside," Anton said.

There is also a page on her website that is dedicated to Eri's Fit Kitchen; it provides recipes for healthy eating.

As Anton noted, she is all about the Fit Life and finding balance. She has undergone her own personal journey of challenges as an immigrant in this country and has found her peace through fitness.

With the launch of her website, redirection of her Instagram account towards health and fitness, writing her own blogs, taking on new endorsement opportunities, training and competing in her first contest (NPC Golden State) in August 2019, developing and launching her Amazon storefront, as well as traveling and doing photo shoots and launching her YouTube channel, 2019 has been an exceptionally busy year for Anton.

In addition, she has also recently designed and launched her own line of fitness clothing called Inspire by Eri Anton.

Anton personally created all the outfits, selected the material, patterns, stitching and colors and designed her own logo to represent the quality and effort she has put into developing her own brand.

"I want to motivate women to accept themselves and be confident and love their bodies in all shapes, sizes and levels of fitness and be the best they can be. A woman's body should not be the standard for her self love and worth," Anton said.

"I'm so proud of the amount of work and effort I've given 2019 both mentally and physically. There's been a lot of blood, sweat and tears poured into this year and I'm proud to say after many failures, it's been very worth it."

About Eri Anton

Eri Anton is a social media fitness star who now has over 1 million followers on Instagram. Her website features blogs and other posts all related to fitness and health, and she strives to motivate women of all shapes and sizes to work hard to be the best they can be. For more information, please visit https://www.erianton.com/.

Contact:

Paula Henderson
phendersonnews@gmail.com
2122238954

SOURCE: Eri Anton

ReleaseID: 569988

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Filed an Amended Complaint to Recover Losses Suffered by Bloom Energy Corporation Investors

NEW YORK, NY / ACCESSWIRE / December 17, 2019 / Levi & Korsinsky, LLP filed an amended complaint against Bloom Energy Corporation ("Bloom Energy") (NYSE:BE) and its officers, directors, and underwriters on November 4, 2019. Levi & Korsinsky filed the amended complaint in its ongoing class action lawsuit pending in the United States District Court for the Northern District of California.

On September 3, 2019, Judge William H. Orrick appointed Levi & Korsinsky as lead counsel for the class action lawsuit. The firm has been actively compiling a case against Bloom Energy by, among other things, reviewing the company's public statements and contacting whistleblowers with evidence of fraud.

If you or someone you know can assist Levi & Korsinsky's active case against Bloom Energy, please contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

To get more information or view copy of Levi & Korsinsky's amended complaint, go to:

https://www.zlk.com/pslra-1/bloom-energy-corporation-loss-form

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 570517

Zimmer Biomet Holdings Facing 19 Jury Trials Over Metal on Metal Hip Replacements

SARASOTA, FL / ACCESSWIRE / December 17, 2019 / Zimmer Biomet Holdings, Inc. (NYSE:ZBH)  (SWX:ZBH) is facing almost 20 jury trials across the country between 2020 through 2021. The barrage of trials begins May 2020 in Seattle, WA and spans venues across the country. The trials involve patients suffering heavy metal poisoning from Biomet metal on metal hip replacements. The patients in these jury trials are all represented by Maglio Christopher & Toale, P.A., which currently has 140 lawsuits filed against Zimmer Biomet.

Biomet has never faced a trial over its M2a metal-on-metal hip replacements, until now. In 2014, before its merger with Zimmer, Biomet claimed a meager $56 million settlement would make the company's metal on metal hip replacement litigation liability go away. It did not. As a result, the new company — Zimmer Biomet — is saddled with litigation problems which continue to get worse.

From the beginning, the attorneys at Maglio Christopher & Toale, P.A filed their clients' cases in state courts around the country instead of the Federal Multi-District Litigation, where most cases were gathered in one court. The independence from the federal MDL allowed them unique access to millions of pages of additional documents as well as many witnesses. "We believe the jury will see that these documents show a shocking disregard for patient safety in the pursuit of profit," says Managing Partner, Altom Maglio. Those documents are currently sealed but will become public during the upcoming trials.

Portions of the case against Zimmer Biomet include:

Damaging and incriminating internal company documents.
Surgeons warnings to Biomet which went ignored.
The company's decision to recall the metal on metal hip replacements in Australia and Europe, but not in the United States.

The attorneys at Maglio Christopher & Toale, PA will have 19 opportunities across the country to present the case against Zimmer Biomet for the public to hear and a jury to decide. For Zimmer Biomet, this represents an immense financial and credibility problem, especially given repeated missed opportunities to resolve these cases.

About Maglio Christopher & Toale, P.A. – MCTLaw

Maglio Christopher & Toale, P.A. is leading the U.S. litigation against metal on metal hip replacements with clients across the country. The Firm filed the first metal on metal (MoM) hip replacement lawsuit in the United States in 2008 and has been continuously litigating these cases ever since.

Contact: Altom Maglio, Managing Partner, Maglio Christopher & Toale, P.A.
Phone: 888.952.5242
Website: https://www.mctlaw.com/joint-replacement/biomet-hip-implant/

SOURCE: Maglio Christopher & Toale, P.A.

ReleaseID: 570395

Baebies Announces CE Mark for FINDER, an Innovative Near-Patient Testing Platform for Glucose-6-Phosphate Dehydrogenase

DURHAM, NC / ACCESSWIRE / December 17, 2019 / Baebies is pleased to announce that FINDERTM, a near-patient testing platform, now has CE Mark as an In Vitro Diagnostic device (IVD) and is commercially available in Europe and other countries that recognize CE Mark. The CE-Marked platform includes an instrument and a cartridge, which tests for Glucose-6-Phosphate Dehydrogenase (G6PD) from low blood volume, a single drop of whole blood (50 μL), with a turn-around time of approximately 15 minutes after sample introduction.

G6PD deficiency is the most common enzyme deficiency worldwide, affecting approximately 400 million people. It can cause a spectrum of diseases including neonatal hyperbilirubinemia (HBR), commonly known as jaundice, acute hemolysis, and chronic hemolysis. "The ability to perform G6PD testing with a near-patient device would have a major impact on our ability to manage hyperbilirubinemia," says Vinod Bhutani, MD, Professor of Pediatrics and Neonatology, Stanford University. "This would be especially valuable in areas of the world with high percentages of African, Asian, Mediterranean or Middle-Eastern descent, to provide a comprehensive profile of treatment and avoidance of stressors."

To aid healthcare professionals in their clinical care for critically ill newborns and children undergoing intensive care, there is a significant need for tests requiring low blood volume. FINDER is specifically designed to address this growing need. FINDER can be used in various distributed settings including hospital nurseries, laboratories, neonatal intensive care units and birthing centers. The innovative, pioneering platform features:

Digital microfluidic technology which minimizes sample and reagent volumes
Small footprint at just 8 inches wide with a tablet for user interface
Simple workflow with only one user step to load sample
All necessary reagents onboard the cartridge, including for sample preparation

"As a company focused on newborn screening and pediatric testing, FINDER's CE Mark allows Baebies to continue to work towards our mission, that everyone deserves a healthy start, by expanding access of testing to more babies around the world," says Richard West, Co-Founder and Chief Executive Officer of Baebies.

FINDER is currently undergoing a clinical trial in the U.S. for Food and Drug Administration (FDA) clearance of the near-patient platform and the test panel that includes testing of G6PD enzyme activity. Baebies plans to complete the FINDER clinical trial in early 2020 for FDA 510(k) submission. Baebies has a robust development pipeline of test panels for various conditions requiring low blood volume to maximize diagnostic yield in neonatal and pediatric patients.

About Baebies

Baebies – guided by the vision that "everyone deserves a healthy start" – develops and commercializes products and services that enable early disease detection and comprehensive diagnosis for children. Baebies' products include SEEKER®, an FDA-authorized and CE-marked high throughput newborn screening platform, and FINDERTM, a CE-marked low volume pediatric testing platform, currently not commercially available in the U.S. Our mission is to save lives and make lives better for all children by bringing new technologies, new tests and new hope to parents and healthcare professionals worldwide. To further our mission, Baebies also provides expanded newborn screening services from its CLIA-certified laboratory. Baebies is headquartered in Durham, North Carolina. For more information visit baebies.com and follow us on LinkedIn, Twitter and YouTube.

CONTACT:

Emily McLoughlin
emcloughlin @ baebies.com
(919) 328-8331

SOURCE: Baebies, Inc.

ReleaseID: 570182

HEXO Shareholder Alert:  January 27, 2020 Filing Deadline in Class Action – Contact Lieff Cabraser

SAN FRANCISCO, CA / ACCESSWIRE / December 17, 2019 / The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in the class action litigation on behalf of investors who purchased or otherwise acquired the common stock of HEXO Corp. ("HEXO" or the "Company") (NYSE:HEXO) between January 25, 2019 and November 15, 2019, inclusive (the "Class Period").

If you purchased or otherwise acquired the common stock of HEXO during the Class Period, you may move the Court for appointment as lead plaintiff by no later than January 27, 2020. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the actions will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the actions.

HEXO investors who wish to learn more about the litigation and how to seek appointment as lead plaintiff should click here or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.

HEXO, incorporated and headquartered in Canada, makes and sells cannabis products for distribution to users, principally through third-party physical and online retailers.

Based on our investigation, we believe HEXO made materially false or misleading statements by (1) providing revenue guidance that materially overstated HEXO's likely revenue for 2020, (2) overstating the number of retail locations for HEXO's product that would be available during the fiscal year of 2019, (3) overstating the value of inventory, and (4) failing to disclose the Company's unlicensed growth of cannabis in Niagara.

After the close of markets on October 4, 2019, HEXO announced the sudden resignation of its new Chief Financial Officer. In response, HEXO's stock price declined 6% to close at $3.80 on October 7, 2019, the next trading day.

Six days later on October 10, 2019, HEXO withdrew its revenue guidance for the fiscal year of 2020 based in part on slow expansion of retail locations in Quebec and Ontario. That day, HEXO's stock price closed at $3.66, or 22% lower than the prior day's closing price.

On October 28, 2019 HEXO announced that it would take an impairment charge as a result of an excess of inventory that was caused in part by the slow expansion of retail locations in Quebec and Ontario. HEXO's stock declined another 6% to close at $2.52 the next day.

Then on November 15, 2019, HEXO belatedly disclosed that it had identified the unlicensed growth of cannabis on a HEXO property on July 30, 2019. That day, HEXO's stock closed at $1.79, a 5% decline from the prior day's closing price.

About Lieff Cabraser

Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York, and Nashville, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.

The National Law Journal has recognized Lieff Cabraser as one of the nation's top plaintiffs' law firms for fourteen years. In compiling the list, the National Law Journal examines recent verdicts and settlements and looked for firms "representing the best qualities of the plaintiffs' bar and that demonstrated unusual dedication and creativity." Law360 has selected Lieff Cabraser as one of the Top 50 law firms nationwide for litigation, highlighting our firm's "laser focus" and noting that our firm routinely finds itself "facing off against some of the largest and strongest defense law firms in the world." Benchmark Litigation has named Lieff Cabraser one of the "Top 10 Plaintiffs' Firms in America."

For more information about Lieff Cabraser and the firm's representation of investors, please visit https://www.lieffcabraser.com/.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Source/Contact for Media Inquiries Only

Sharon M. Lee
Lieff Cabraser Heimann & Bernstein, LLP
Telephone: 1-800-541-7358

SOURCE: Lieff Cabraser Heimann & Bernstein

ReleaseID: 570409

Plantronics Shareholder Alert: January 13, 2020 Filing Deadline in Class Action – Contact Lieff Cabraser

SAN FRANCISCO, CA / ACCESSWIRE / December 17, 2019 / The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in the class action that has been filed on behalf of investors who purchased or otherwise acquired the securities of Plantronics, Inc. ("Plantronics" or the "Company") (NYSE:PLT) between January 2, 2018 and November 5, 2019, inclusive (the "Class Period").

If you purchased or otherwise acquired Plantronics securities during the Class Period, you may move the Court for appointment as lead plaintiff by no later than January 13, 2020. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the actions will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the actions.

Plantronics investors who wish to learn more about the litigation and how to seek appointment as lead plaintiff should click here or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.

Plantronics, incorporated in Delaware and headquartered in Santa Cruz, California, designs, manufactures, and markets integrated communications and collaboration solutions.

Plaintiffs allege that, throughout the Class Period, Plantronics made materially false or misleading statements, failing to disclose that (1) the Company had engaged in channel stuffing to artificially increase its sales; (2) the Company's internal controls over inventory levels were not effective; and (3) the Company had not adequately monitored inventory levels leading up to multiple product launches.

On November 5, 2019, Plantronics disclosed a $65 million reduction in channel inventory "by reducing sales to channel partners" and significantly lowered its fiscal 2020 guidance. The same day, Plantronics announced that the Executive Vice President of Global Sales, Jeff Loebbaka, was departing the Company. On that news, the price of Plantronics common stock fell $14.44 per share, or 36.61%, from a closing price of $39.44 on November 5, 2019, to close at $25.00 per share on November 6, 2019, on extremely elevated trading volume.

About Lieff Cabraser

Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York, and Nashville, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.

The National Law Journal has recognized Lieff Cabraser as one of the nation's top plaintiffs' law firms for fourteen years. In compiling the list, the National Law Journal examines recent verdicts and settlements and looked for firms "representing the best qualities of the plaintiffs' bar and that demonstrated unusual dedication and creativity." Law360 has selected Lieff Cabraser as one of the Top 50 law firms nationwide for litigation, highlighting our firm's "laser focus" and noting that our firm routinely finds itself "facing off against some of the largest and strongest defense law firms in the world." Benchmark Litigation has named Lieff Cabraser one of the "Top 10 Plaintiffs' Firms in America."

For more information about Lieff Cabraser and the firm's representation of investors, please visit https://www.lieffcabraser.com.

Follow us for updates on Twitter: https://twitter.com/LieffCabraser.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Source/Contact for Media Inquiries Only

Sharon M. Lee
Lieff Cabraser Heimann & Bernstein, LLP
Telephone: 1-800-541-7358

SOURCE: Lieff Cabraser Heimann & Bernstein, LLP

ReleaseID: 570408

Under Armour Investor Alert:  January 6, 2020 Filing Deadline in Class Action – Contact Lieff Cabraser

SAN FRANCISCO, CA / ACCESSWIRE / December 17, 2019 / The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in the class action litigation on behalf of investors who purchased or otherwise acquired the securities of Under Armour, Inc., ("Under Armour" or the "Company") (NYSE:UA; UAA) between August 3, 2016 and November 1, 2019, inclusive (the "Class Period").

If you purchased or otherwise acquired the securities of Under Armour during the Class Period, you may move the Court for appointment as lead plaintiff by no later than January 6, 2020. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the actions will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the actions.

Under Armour investors who wish to learn more about the litigation and how to seek appointment as lead plaintiff should click here or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.

Background on the Under Armour Securities Class Litigation

Under Armour, based in Baltimore, Maryland, develops, markets, and distributes branded performance apparel, footwear, and accessories for men, women, and youth.

The action alleges that during the Class Period, Under Armour made false and/or misleading statements and/or failed to disclose that: (i) Under Armour improperly shifted sales from quarter to quarter to keep pace with their long-running year-over-year 20% net revenue growth; (ii) the Company had been subject to federal accounting probes since at least July 2017; and (iii) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On November 3, 2019, The Wall Street Journal reported that the U.S. Department of Justice ("DOJ") and the Securities Exchange Commission ("SEC") are investigating whether Under Armour shifted sales from quarter to quarter to appear healthier. On the following day, Under Armour confirmed that it was under DOJ and SEC investigations and has been responding to requests for documents and information regarding certain of its accounting practices and related disclosures, beginning with submissions to the SEC in July 2017. Following this news, the price of Under Armour Class A common stock fell $4.00 per share, or nearly 18.9%, to close at $17.14 per share, and its Class C common stock fell $3.47 per share, or 18.3%, to close at $15.44 per share.

About Lieff Cabraser

Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York, and Nashville, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.

The National Law Journal has recognized Lieff Cabraser as one of the nation's top plaintiffs' law firms for fourteen years. In compiling the list, the National Law Journal examines recent verdicts and settlements and looked for firms "representing the best qualities of the plaintiffs' bar and that demonstrated unusual dedication and creativity." Law360 has selected Lieff Cabraser as one of the Top 50 law firms nationwide for litigation, highlighting our firm's "laser focus" and noting that our firm routinely finds itself "facing off against some of the largest and strongest defense law firms in the world." Benchmark Litigation has named Lieff Cabraser one of the "Top 10 Plaintiffs' Firms in America."

For more information about Lieff Cabraser and the firm's representation of investors, please visit https://www.lieffcabraser.com/.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Source/Contact for Media Inquiries Only

Sharon M. Lee
Lieff Cabraser Heimann & Bernstein, LLP
Telephone: 1-800-541-7358

SOURCE: Lieff Cabraser Heimann & Bernstein

ReleaseID: 570407

iRobot Shareholder Alert: December 23, 2019 Filing Deadline in Class Action – Contact Lieff Cabraser

SAN FRANCISCO, CA / ACCESSWIRE / December 17, 2019 / The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in the class action that has been filed on behalf of investors who purchased or otherwise acquired the stock of iRobot Corporation ("iRobot" or the "Company") (NASDAQ:IRBT) between November 21, 2016 and October 22, 2019, inclusive of (The "Class Period").

If you purchased or otherwise acquired the common stock of iRobot during the Class Period, you may move the Court for appointment as lead plaintiff by no later than December 23, 2019. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the actions will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the actions.

iRobot investors who wish to learn more about the litigation and how to seek appointment as lead plaintiff should click here or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.

iRobot is a global consumer robot company that designs and builds robots to assist with household tasks. iRobot's most popular product is its Roomba line of autonomous robotic vacuum cleaners.

The actions allege that, throughout the Class Period, iRobot reported double-digit revenue growth, which it attributed to increasing demand for its Roomba products, and expanded gross margin due to distributor acquisitions, greater brand awareness and technological innovation. Unbeknownst to investors, iRobot was engaging in channel-stuffing in order to inflate its sales and revenues figures, and had acquired two of its largest distributors in order to facilitate and conceal this deceptive practice.

On April 23, 2019, after the close of trading, iRobot announced that its quarterly revenues were below analyst expectations and revealed surging inventory levels. Specifically, iRobot reported days in inventory ("DII") of 140 for the three months ended March 30, 2019, compared to DII of 101 for the same period in the year prior. Inventory also rose to $181 million as of March 30, 2019, up from $112 million in April 2018. Following this news, the price of iRobot's stock fell $30.15 per share, or more than 23%, to close at $100.42 per share on April 24, 2019.

On July 23, 2019, after the close of trading, iRobot cut its full-year fiscal 2019 revenue guidance as well as its earnings per share guidance. Following this news, iRobot's stock price fell from $15.12 per share, or nearly 17%, to close at $74.51 per share on July 24, 2019.

On October 22, 2019, after the close of trading, iRobot reported its third quarter 2019 financial results and cut the high end of its revenue expectations for the year. iRobot said it rolled back price increases after a "suboptimal" customer response. In addition, iRobot reported increased inventory levels once again, with third quarter 2019 ending inventory of $248 million or 149 DII compared to the $161 million or 113 DII a year prior. Following this news, iRobot's stock price fell $4.97 per share, or 9.2%, to close at $49.06 per share on October 23, 2019.

About Lieff Cabraser

Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York, and Nashville, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.

The National Law Journal has recognized Lieff Cabraser as one of the nation's top plaintiffs' law firms for fourteen years. In compiling the list, the National Law Journal examines recent verdicts and settlements and looked for firms "representing the best qualities of the plaintiffs' bar and that demonstrated unusual dedication and creativity." Law360 has selected Lieff Cabraser as one of the Top 50 law firms nationwide for litigation, highlighting our firm's "laser focus" and noting that our firm routinely finds itself "facing off against some of the largest and strongest defense law firms in the world." Benchmark Litigation has named Lieff Cabraser one of the "Top 10 Plaintiffs' Firms in America."

For more information about Lieff Cabraser and the firm's representation of investors, please visit https://www.lieffcabraser.com.

Follow us for updates on Twitter: https://twitter.com/LieffCabraser.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Source/Contact for Media Inquiries Only

Sharon M. Lee
Lieff Cabraser Heimann & Bernstein, LLP
Telephone: 1-800-541-7358

SOURCE: Lieff Cabraser Heimann & Bernstein

ReleaseID: 570405

Point Loma Resources Announces Transaction Involving Asset Swap and Cash Injection for Its Wizard Lake Property

CALGARY, AB / ACCESSWIRE / December 17, 2019 / Point Loma Resources Ltd. (TSXV:PLX) ("Point Loma" or the "Corporation") is pleased to announce a transaction to rationalize its assets and monetize its working interest at Wizard Lake, Alberta.

Highlights

Point Loma has entered into a Purchase and Sale agreement ("PSA") with White Bark Energy Ltd. (WBE:ASX, "White Bark"), the parent company of Salt Bush Energy Ltd. ("Salt Bush"), to transfer its working interests in the Wizard Lake area to Salt Bush for consideration of $6.8 million in the form of $4.0 million cash (the "Cash Consideration"), $2.0 million of stock in White Bark, the reduction of outstanding payout amounts of approximately $0.8 million and the transfer from Salt Bush to Point Loma of approximately 240 boepd (based on Q3 producing rates) of its current working interests in various other joint properties in Alberta (the "Transaction"). Additionally, Point Loma retains a 10% working interest in certain Wizard Lake area assets until December 31, 2020, which is expected to provide the Corporation with additional revenues through 2020.

The Transaction is scheduled to be completed over three closings. Pursuant to the PSA, Point Loma will receive $1.2 million of the Cash Consideration on completion of the first closing, anticipated in late-December 2019, with the balance of $2.8 million on the second closing, which is anticipated prior to March 31, 2020, subject to a financing by White Bark and receipt of regulatory approvals. Share consideration in connection with the Transaction will be $2.0 million issued on completion of the second closing with $1.0 million held in escrow for 4 months and another $1.0 million released upon final closing, on or about December 31, 2020, subject to receipt of regulatory approvals.

The funds from the Transaction will be utilized to commence a multi-stage corporate turnaround plan.

The additional production associated with the properties transferred to the Corporation is expected to supplement Point Loma's revenues immediately upon completion of the first closing.

The Transaction is expected to increase Point Loma's net acreage to approximately 165,000 acres, where the Corporation has identified future locations and opportunities analogous to Point Loma's Wizard lake discovery.

Proposed Transaction

Point Loma has invested approximately $3.0 million to date at Wizard Lake. Pursuant to the Transaction, Point Loma will receive $6.0 million in cash and White Bark stock, approximately 240 boepd of working interest production and see a working capital deficit reduction of approximately $0.8 million associated with the cancellation of a facility payout account.

"This transaction points to further potential upside on Point Loma's large 165,000 net acreage position and deep inventory of oil opportunities," said Terry Meek, President and CEO of Point Loma.

Mackie Research Capital Corporation acted as the sole financial advisor to Point Loma Resources with respect to the marketing of the Company's Rex Oil assets and the Transaction.

Point Loma maintains an extensive inventory of additional opportunities identified through analysis of historical penetrations that are indicative of bypassed oil pay on its lands. A description of the Corporation's other oil pool development opportunities can be found in the corporate presentation on the Point Loma website at www.pointloma.ca.

About Point Loma

Point Loma is a public oil and gas exploration and development company focused on conventional and unconventional oil and gas reservoirs in west central Alberta. The Corporation controls over 165,000 net acres (250 net sections) and has a deep inventory of oil opportunities in the Mannville (Upper and Lower), Banff, Nordegg, and Duvernay Shale formations. Point Loma's business plan is to utilize its experience to drill, develop and acquire accretive assets with potential to employ horizontal multi-stage frac technology and to exploit opportunities for secondary recovery. For more information, please visit Point Loma's website at www.pointloma.ca or Point Loma's profile on the System for Electronic Document Analysis and Retrieval website at www.sedar.com.

For further information, please contact:

Terry Meek
President and CEO
Telephone: (403) 705-5051 ext. 444
tmeek@pointloma.ca

Thomas Love
VP Finance and CFO
Telephone: (403) 705-5051 ext. 443
tlove@pointloma.ca

A Note Regarding Forward-Looking Information

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws, including without limitation, statements pertaining to the expected revenues from Point Loma's working interest in the Wizard Lake area; the anticipated timing to complete the Transaction, including the expected schedule of multiple closings and whether such closings will be completed; the anticipated use of funds from the Transaction; the expected impact of the Transaction on Point Loma's net acreage; statements relating to Point Loma's expectations about the potential impacts of the Transaction; expected net profits and working capital deficit reduction in connection with the Wizard Lake property; the focus of Point Loma's management team and go-forward strategy; and statements. Statements relating to "reserves" are also deemed to forward-looking statements, as they involve the implied assessment based on certain estimates and assumptions, that the reserves can be profitably produced in the future.

The use of any of the words "will", "could", "would", "expects", "believe", "plans", "potential" and similar expressions are intended to identify forward-looking statements or information. These statements should not be read as guarantees of future performance or results. Although Point Loma believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because Point Loma cannot give assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited, delays or changes associated with consummation of the Transaction; the inability to obtain the necessary regulatory approvals; the risks associated with the oil and gas industry in general such as operational risks in development, exploration and production; delays or changes in plans with respect to exploration or development projects or capital expenditures; the uncertainty of reserve and resource estimates; the inability of Point Loma to bring additional production on stream or in the anticipated quantities disclosed herein; the uncertainty of estimates and projections relating to reserves, resources, production, costs and expenses; health, safety and environmental risks; commodity price and exchange rate fluctuations; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of acquisitions; failure to realize the anticipated benefits of acquisitions; ability to access sufficient capital from internal and external sources; changes in legislation, including but not limited to tax laws, royalties and environmental regulations, actual production from the acquired assets may be greater or less than estimates. Management has included the above summary of assumptions and risks related to forward-looking information provided in this press release in order to provide security holders with a more complete perspective on Point Loma's future operations and such information may not be appropriate for other purposes.

The forward-looking statements and information contained in this press release are made as of the date hereof and Point Loma does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Oil and Gas Information

"BOEs" may be misleading, particularly if used in isolation. A BOE conversion ratio of six thousand cubic feet of natural gas to one barrel of oil equivalent (6 Mcf: 1 bbl) is based on an energy equivalency conversion method primarily applicable at the burner tip and does not represent a value equivalency at the wellhead. As the value ratio between natural gas and crude oil based on the current prices of natural gas and crude oil is significantly different from the energy equivalency of 6:1, utilizing a conversion on a 6:1 basis may be misleading as an indication of value.

Well test results should be considered as preliminary. Neither a pressure transient analysis nor a well-test interpretation has been carried out on the well test data contained herein and therefore the data contained herein should be considered to be preliminary until such analysis or interpretation has been done. There is no representation by the Corporation that the disclosed well results included in this news release are necessarily indicative of long term performance or recovery. As a result, readers are cautioned not to place reliance on such rates in calculating the aggregate production for the Corporation or that such rates are indicative of future performance of the well.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Point Loma Resources Ltd.

ReleaseID: 570464

Baxter Shareholder Alert: January 24, 2020 Filing Deadline in Class Action- Contact Lieff Cabraser

SAN FRANCISCO, CA / ACCESSWIRE / December 17, 2019 / The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the upcoming deadline to move for appointment as lead plaintiff in the class action that has been filed on behalf of investors who purchased or otherwise acquired the securities of Baxter International Inc. ("Baxter" or the "Company") (NYSE:BAX) between February 21, 2019 and October 23, 2019, inclusive (the "Class Period").

If you purchased or otherwise acquired the securities of Baxter during the Class Period, you may move the Court for appointment as lead plaintiff by no later than January 24, 2020. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the actions will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the actions.

Baxter investors who wish to learn more about the litigation and how to seek appointment as lead plaintiff should click here or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.

Background on the Baxter Securities Class Litigation

Baxter, based in Deerfield, Illinois, provides a broad portfolio of essential healthcare products, including acute chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, and surgical hemostat and sealant products.

The action alleges that during the Class Period, Baxter and certain of its officers made materially false and/or misleading statements and/or failed to disclose that: (i) certain intra-Company transactions, undertaken for the purpose of generating foreign exchange gains and losses, used foreign exchange rate conventions that were not in accordance with Generally Accepted Accounting Principles ("GAAP") and enabled intra-Company transactions to be undertaken after the related exchange rates were already known; 2) the Company lacked effective internal control over its financial reporting; (3) as a result, the Company's financial statements were misstated and would likely necessitate correction or amendment; (4) due to the Company's internal investigation, Baxter would not be able to timely file its quarterly report for the period ending September 30, 2019 with the Securities and Exchange Commission ("SEC") on Form 10-Q in a timely manner; and (5) as a result of the foregoing, Baxter and its officers' statements about the Company's business and operations lacked a reasonable basis at all relevant times.

On October 24, 2019, Baxter announced that it "recently began an investigation into certain intra-Company transactions undertaken for the purpose of generating foreign exchange gains or losses," and that according to the Company, "[t]hese transactions used a foreign exchange rate convention historically applied by the Company that was not in accordance with generally accepted accounting principles ("GAAP") and enabled intra-Company transactions to be undertaken after the related exchange rates were already known." The Company also admitted that these intra-Company transactions had "resulted in certain misstatements in the Company's previously reported non-operating income related to net foreign exchange gains" and acknowledged that upon completion of its investigation, "the Company expects to either amend its periodic reports previously filed with the SEC to include restated financial statements that correct those misstatements, or include in reports for future periods restated comparative financial statements that correct those misstatements." Following this news, the price of Baxter common stock fell $8.87 per share, or 10.1%, from a close of $87.95 per share on October 23, 2019 to close at $79.08 per share on October 24, 2019, on elevated trading volume.

About Lieff Cabraser

Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York, and Nashville, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.

The National Law Journal has recognized Lieff Cabraser as one of the nation's top plaintiffs' law firms for fourteen years. In compiling the list, the National Law Journal examines recent verdicts and settlements and looked for firms "representing the best qualities of the plaintiffs' bar and that demonstrated unusual dedication and creativity." Law360 has selected Lieff Cabraser as one of the Top 50 law firms nationwide for litigation, highlighting our firm's "laser focus" and noting that our firm routinely finds itself "facing off against some of the largest and strongest defense law firms in the world." Benchmark Litigation has named Lieff Cabraser one of the "Top 10 Plaintiffs' Firms in America."

For more information about Lieff Cabraser and the firm's representation of investors, please visit https://www.lieffcabraser.com/.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Source/Contact for Media Inquiries Only

Sharon M. Lee
Lieff Cabraser Heimann & Bernstein, LLP
Telephone: 1-800-541-7358

SOURCE: Lieff Cabraser Heimann & Bernstein, LLP

ReleaseID: 570403